Intuitive Ventures

Capstan Medical is creating minimally invasive technologies to treat heart valve disorders.

XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

Capstan Medical is creating minimally invasive technologies to treat heart valve disorders.

SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.

Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Dasera, Inc. is a data security company based in Sunnyvale, California, that specializes in developing a query analysis engine designed to enhance data safety in organizational environments. Established in 2019, Dasera's platform automates security and governance controls for both structured and unstructured data across cloud, on-premises, and hybrid systems. By monitoring query behavior, the engine identifies and rewrites unsafe queries, thereby minimizing the risk of insider breaches and ensuring compliance with data privacy regulations. Dasera's solutions empower organizations to manage risk throughout the entire data lifecycle, from creation to deletion, ultimately fostering trust between consumers and companies in the sensitive handling of data.

MedCrypt Inc. is a cybersecurity company specializing in the protection of medical devices. Founded in 2016 and based in Encinitas, California, MedCrypt provides data security solutions for a wide range of medical devices, including implantable devices like pacemakers and various surgical robots. The company's platform offers data security as a service to medical device original equipment manufacturers (OEMs), enabling them to implement essential security features quickly and efficiently. These features include user authentication, data encryption, and transaction monitoring to detect potential malicious behavior. By integrating security capabilities into medical devices with minimal code, MedCrypt allows engineers to focus on developing innovative clinical functionalities while ensuring the safety and integrity of device operations.

Neocis, Inc. is a Miami-based company that specializes in robotic guidance systems for dental implant procedures. Founded in 2009, Neocis develops the Yomi system, a robotic device designed to enhance the precision of dental surgeries. Yomi integrates computer imagery from CT scans with surgical planning, providing dental surgeons with multi-sensory feedback during procedures. This technology aims to transform dental surgery by offering a minimally invasive approach, which can lead to faster recovery times for patients. The Yomi system has received clearance from the U.S. Food and Drug Administration and is commercially available in the United States, underscoring Neocis's commitment to advancing patient care and addressing the challenges faced by dental professionals.

SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.

Optellum Ltd is a company based in Oxford, United Kingdom, specializing in the development of AI-driven clinical decision support software for lung cancer diagnosis and treatment. Founded in 2015, Optellum aims to enhance cancer care by providing an end-to-end IT platform that facilitates personalized early diagnosis and therapeutic strategies for patients at high risk of developing lung cancer, which is the most common and deadliest form of cancer. The company's innovative software identifies at-risk individuals and streamlines optimal treatment options, leveraging machine learning to analyze vast datasets from numerous healthcare professionals. Optellum's team consists of experts in medical imaging, artificial intelligence, and clinical practice, many of whom have a history of successful innovations in the medical technology sector. They are supported by an advisory board of leading clinicians and deep learning specialists, and are actively expanding their product development team to further their mission in the fight against cancer.

Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

KelaHealth, Inc. is a company that specializes in developing clinical decision support software tailored for surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering recommendations to mitigate these issues. By harnessing patient data, the platform aims to enhance the quality of surgical care and operational efficiency. It provides patient-specific insights and suggested interventions at critical decision points, creating a learning ecosystem that fosters continuous improvement in surgical outcomes. Additionally, KelaHealth's technology helps standardize practices among surgeons and addresses the administrative and regulatory requirements for quality compliance in surgical operations, ultimately assisting physicians and hospital administrators in better assessing patient risk and enhancing surgical quality.

KelaHealth, Inc. is a company that specializes in developing clinical decision support software tailored for surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering recommendations to mitigate these issues. By harnessing patient data, the platform aims to enhance the quality of surgical care and operational efficiency. It provides patient-specific insights and suggested interventions at critical decision points, creating a learning ecosystem that fosters continuous improvement in surgical outcomes. Additionally, KelaHealth's technology helps standardize practices among surgeons and addresses the administrative and regulatory requirements for quality compliance in surgical operations, ultimately assisting physicians and hospital administrators in better assessing patient risk and enhancing surgical quality.